drugset / Trial / NCT04543344
Study To Evaluate The Pharmacokinetic, Safety And Tolerability Of Single Or Multiple Subcutaneous Doses of Recifercept
RandomizedParallel-groupDouble-blindTreatment
Summary
This will be a single center, randomized, parallel group, repeated dose study of recifercept (Cohort 1 and Cohort 2) or placebo (only in Cohort 1) in approximately 18 healthy participants, using 2 cohorts (N = 9) at two dose levels of recifercept.
Timeline
- Start
- 2020-09-17
- Primary completion
- 2021-08-03
- Completion
- 2021-11-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Recifercept | Protein / enzyme biologic | — | Subcutaneous |
Indications
No indication recorded.